HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens-Reference-Cited by-同舟云学术

HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens

Published:2018-05-08 Issue:8 Volume:25 Page:969-975
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Boyd S. D.¹^ORCID,Harrington P.¹,Komatsu T. E.¹,Naeger L. K.¹,Chan-Tack K.¹,Murray J.¹,Birnkrant D.¹,Struble K.¹

Affiliation:

1. Center for Drug Evaluation and Research; Office of Antimicrobial Products; Division of Antiviral Products, Food and Drug Administration; Silver Spring MD USA

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12896/fullpdf

Reference49 articles.

1. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey;Dibonaventura;PLoS ONE,2014

2. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients;Fattovich;Gastroenterology,1997

3. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients;Planas;J Hepatol,2004

4. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

5. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C;Backus;Clin Gastroenterol Hepatol,2011

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

2. Inorganic–organic hybrid capsules for efficient intracellular delivery of antiviral agents to disinfect and treat virus infections;Smart Nanomaterials to Combat the Spread of Viral Infections;2023

3. Biomedical Applications of Antiviral Nanohybrid Materials Relating to the COVID-19 Pandemic and Other Viral Crises;Polymers;2021-08-23

4. Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection;Journal of Viral Hepatitis;2020-06-26

5. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies;Liver International;2020-06-11